LYL273 for Patients With Relapsed or Refractory mCRC | MicrobiomeTrials← Back to trialsNCT05319314
LYL273 for Patients With Relapsed or Refractory mCRC
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-08-01Est. Completion: 2028-06
Enrollment target: 155 participants Locations- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California San Francisco Medical Center, San Francisco, California, United States
- University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland CancerPancreatic CancerHER-2 Protein Overexpression
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with p…
Prescott, United StatesEst. completion Dec 31, 2026
Recruiting
The purpose of this study is to study the impact of Western lifestyle, including moderate alcohol consumption and delaye…
Chicago, United StatesEst. completion May 31, 2023